Literature DB >> 10706614

Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

M K Ahlijanian1, N X Barrezueta, R D Williams, A Jakowski, K P Kowsz, S McCarthy, T Coskran, A Carlo, P A Seymour, J E Burkhardt, R B Nelson, J D McNeish.   

Abstract

Hyperphosphorylation of microtubule-associated proteins such as tau and neurofilament may underlie the cytoskeletal abnormalities and neuronal death seen in several neurodegenerative diseases including Alzheimer's disease. One potential mechanism of microtubule-associated protein hyperphosphorylation is augmented activity of protein kinases known to associate with microtubules, such as cdk5 or GSK3beta. Here we show that tau and neurofilament are hyperphosphorylated in transgenic mice that overexpress human p25, an activator of cdk5. The p25 transgenic mice display silver-positive neurons using the Bielschowsky stain. Disturbances in neuronal cytoskeletal organization are apparent at the ultrastructural level. These changes are localized predominantly to the amygdala, thalamus/hypothalamus, and cortex. The p25 transgenic mice display increased spontaneous locomotor activity and differences from control in the elevated plus-maze test. The overexpression of an activator of cdk5 in transgenic mice results in increased cdk5 activity that is sufficient to produce hyperphosphorylation of tau and neurofilament as well as cytoskeletal disruptions reminiscent of Alzheimer's disease and other neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706614      PMCID: PMC16029          DOI: 10.1073/pnas.040577797

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Abnormal processing of multiple proteins in Alzheimer disease.

Authors:  H Zhang; N H Sternberger; L J Rubinstein; M M Herman; L I Binder; L A Sternberger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments.

Authors:  K Ishiguro; M Takamatsu; K Tomizawa; A Omori; M Takahashi; M Arioka; T Uchida; K Imahori
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

3.  Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control.

Authors:  S Forss-Petter; P E Danielson; S Catsicas; E Battenberg; J Price; M Nerenberg; J G Sutcliffe
Journal:  Neuron       Date:  1990-08       Impact factor: 17.173

4.  Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding.

Authors:  G T Bramblett; M Goedert; R Jakes; S E Merrick; J Q Trojanowski; V M Lee
Journal:  Neuron       Date:  1993-06       Impact factor: 17.173

5.  Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ.

Authors:  L A Sternberger; N H Sternberger
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

6.  The use of a plus-maze to measure anxiety in the mouse.

Authors:  R G Lister
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast.

Authors:  G Viale; M Gambacorta; G Coggi; P Dell'Orto; M Milani; C Doglioni
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

8.  Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location.

Authors:  G I Szendrei; V M Lee; L Otvos
Journal:  J Neurosci Res       Date:  1993-02-01       Impact factor: 4.164

9.  The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region.

Authors:  J Biernat; E M Mandelkow; C Schröter; B Lichtenberg-Kraag; B Steiner; B Berling; H Meyer; M Mercken; A Vandermeeren; M Goedert; E Mandelkow
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

10.  Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation.

Authors:  U Wagner; M Utton; J M Gallo; C C Miller
Journal:  J Cell Sci       Date:  1996-06       Impact factor: 5.285

View more
  102 in total

1.  Telling tails.

Authors:  M B Kennedy; P Manzerra
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

2.  Genetic modifiers of tauopathy in Drosophila.

Authors:  Joshua M Shulman; Mel B Feany
Journal:  Genetics       Date:  2003-11       Impact factor: 4.562

3.  CDK5 interacts with Slo and affects its surface expression and kinetics through direct phosphorylation.

Authors:  Jun-Ping Bai; Alexei Surguchev; Powrnima Joshi; Liza Gross; Dhasakumar Navaratnam
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-16       Impact factor: 4.249

4.  NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Authors:  Yousuf O Ali; Kai Ruan; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

5.  Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain.

Authors:  Hongwen Zhu; Jennifer J O'Brien; James P O'Callaghan; Diane B Miller; Qiang Zhang; Minal Rana; Tiffany Tsui; Youyi Peng; John Tomesch; Joseph P Hendrick; Lawrence P Wennogle; Gretchen L Snyder
Journal:  Brain Res       Date:  2010-04-25       Impact factor: 3.252

6.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

7.  Leptin signaling and Alzheimer's disease.

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

8.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.

Authors:  Patrice D Smith; Stephen J Crocker; Vernice Jackson-Lewis; Kelly L Jordan-Sciutto; Shawn Hayley; Matthew P Mount; Michael J O'Hare; Steven Callaghan; Ruth S Slack; Serge Przedborski; Hymie Anisman; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

Review 9.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

Review 10.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.